'Per­fect time': SIGA's CEO on re­tire­ment; Ju­ve­nes­cence woos GSK vet to lead an­ti-ag­ing play

In the 1990s, Phil Gomez re­calls the UK gov­ern­ment launch­ing what would be akin to a qua­si-Op­er­a­tion Warp Speed in to­day’s par­lance, as the re­gion was fac­ing high cas­es of menin­gi­tis C in chil­dren un­der the age of 5.

The chem­i­cal en­gi­neer by train­ing was work­ing at North Amer­i­can Vac­cine and helped the com­pa­ny launch a jab to help cur­tail the toll in the UK. He grew an ap­pre­ci­a­tion for pub­lic-pri­vate part­ner­ships, es­pe­cial­ly when na­tion­al gov­ern­ments and the bio­phar­ma and vac­cine man­u­fac­tur­ing in­dus­tries align.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER